Navigation Links
A large step forward in the fight against African sleeping sickness

s not neutralized by Trypanosoma brucei rhodesiense. This truncated ApoL-1 variant can help to overcome the parasite that infects our body, but only when it is present in very high concentrations. The challenge for the researchers was to get this truncated ApoL-1 variant efficiently to the place where it is needed: onto the surface of the parasite.

Nanobody carries ApoL-1 variant to the parasite
Under the direction of Serge Muyldermans and Patrick De Baetselier, VIB researchers have previously produced a nanobody (a very small antibody) that targets and binds to the parasite very specifically (Stijlemans et al., 2004). Toya Nath Baral and his VIB colleagues have now succeeded in coupling this nanobody to the abbreviated ApoL-1 variant. This creates a special product that binds immediately to the parasite and thus brings the ApoL-1 variant to the place where it can carry out its neutralizing action.

All the tests performed on mice have been very promising: Trypanosome-infected mice survive after 1 treatment. The parasite is removed from the blood and all effects associated with the disease disappear. There is every indication that this substance can also counteract Trypanosoma brucei rhodesiense in humans − sparing them from African sleeping sickness.


'"/>

Source:VIB, Flanders Interuniversity Institute of Biotechnology


Page: 1 2

Related biology news :

1. Scientists discover unique microbe in Californias largest lake
2. Worlds largest rainforest drying experiment completes first phase
3. NASA study finds snow melt causes large ocean plant blooms
4. New project aims to make large-scale lobster farms feasible
5. Butterfly migration could be largest known
6. Amazon symposium to address large-scale conservation
7. Inhaling large amounts of salt can cause hypertension
8. Size matters: Preventing large mammal extinction
9. Carnegie Mellon University research reveals how cells process large genes
10. Updated data on novel HPV vaccine confirms efficacy in large population
11. Free-energy theory borne out in large-scale protein folding
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: large step forward the fight against African sleeping sickness

(Date:3/10/2015)... 10, 2015  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing ... wallet has been named the "Number One Best ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a ... home and lifestyle that have a unique function or ...
(Date:3/2/2015)... Calif. , March 2, 2015 ... leading developer of human interface solutions, today announced ... that is designed to enable rapid and secure ... ID™ module for gaming is a turnkey solution ... the ability to quickly integrate fingerprint ID solutions ...
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11
... heterococcus sp. DN1 , which may prove ... in the snow fields of the Rocky Mountains. Research examining ... H. sp. DN1 was found to grow at temperatures ... H. sp. DN1 produces the highest quantity of ...
... in families, researchers at Johns Hopkins have found that ... team up to increase the risk of schizophrenia. They ... Psychiatry , bring some clarity to the murky relationship ... genetic test that can predict which medications will be ...
... in an experiment conducted at the University of Wisconsin-Madison ... model ALS, a nerve disease that destroys nerve control ... (amyotrophic lateral sclerosis) is sometimes called "Lou Gehrig,s disease." ... 5,600 Americans each year. Only about half of patients ...
Cached Biology News:Family studies suggest rare genetic mutations team up to cause schizophrenia 2Engineered stem cell advance points toward treatment for ALS 2Engineered stem cell advance points toward treatment for ALS 3
(Date:3/26/2015)... CINCINNATI , March 26, 2015 ... NASDAQ: SHPG ) and Cincinnati Children,s Hospital ... collaboration for rare diseases. The goal of the collaboration ... treat rare diseases with high unmet medical need ... Children,s research expertise. As a nationally ranked hospital, ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, ... at Align Technology, on “ Conducting Postmarket Registries - ... Global Conference and Exhibition on April 25th through April ... the poster presentation, Ale Gicqueau and Victor Chen will ... Registry, the requirements and resources to conduct the registry, ...
(Date:3/25/2015)... March 25, 2015 Optimal Research, LLC has ... Excellence (ViE) Award "Best Clinical Site or Trial Network". ... Optimal has been selected as a nominee in this ... a "Highly Recommended" distinction in 2014. The ViE awards ... efforts, accomplishments, and positive contributions of companies and individuals ...
(Date:3/25/2015)... and REYKJAVIK, Iceland , March 25, 2015 ... the genome to create better medicine, today congratulated the scientists ... of whole-genome data yet undertaken. The studies ... – are built around the most comprehensive population-wide tally ... deCODE scientists led by Kari Stefansson , deCODE,s founder ...
Breaking Biology Technology:Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2
... , , SEATTLE, Nov. 19 Omeros Corporation (Nasdaq: ... quarter ended September 30, 2009. For the three months ended September ... $1.34 per share, as compared to a net loss of $7.4 ... For the nine months ended September 30, 2009, the Company reported ...
... MALVERN, Pa. and WALTHAM, Mass., Nov. 19 Arlington ... leading driver of antibiotic selection in nosocomial pneumonia in ... Due to the variety of organisms that can cause ... primarily for agents that provide appropriate coverage against common ...
... ... aid. , ... CA (PRWEB) November 16, 2009 -- Popular Science Magazine has named the Lyric “invisible” ... Award in the Health category.    Chosen from thousands of entrants, Lyric is designed to reside ...
Cached Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
... Thermomixer R offers maximum application versatility ... heating, and cooling. Its active heating/cooling ... and temperature control ranges. Five different ... micro test tubes, are available for: ...
Rabbit polyclonal antibody to GluR2...
Mouse monoclonal antibody raised against a partial recombinant TPR. NCBI Entrez Gene ID = TPR...
... Array II can be used to test ... proteins and sera that are commonly used ... array contains spots for 19 different protein ... of antibody crossreactivity and species specificity, QC ...
Biology Products: